T
Thomas J. Blacklock
Researcher at Novartis
Publications - 154
Citations - 3171
Thomas J. Blacklock is an academic researcher from Novartis. The author has contributed to research in topics: Catalysis & Enantioselective synthesis. The author has an hindex of 33, co-authored 154 publications receiving 3053 citations. Previous affiliations of Thomas J. Blacklock include Merck & Co..
Papers
More filters
Journal ArticleDOI
A practical enantioselective synthesis of .alpha.,.alpha.-diaryl-2-pyrrolidinemethanol. Preparation and chemistry of the corresponding oxazaborolidines
David J. Mathre,Todd K. Jones,Lyndon C. Xavier,Thomas J. Blacklock,Robert A. Reamer,Julie J. Mohan,E. Tracy Turner Jones,Karst Hoogsteen,Mary W. Baum,Edward J. J. Grabowski +9 more
Journal ArticleDOI
An asymmetric synthesis of MK-0417. Observations on oxazaborolidine-catalyzed reductions
Todd K. Jones,Julie J. Mohan,Lyndon C. Xavier,Thomas J. Blacklock,David J. Mathre,Paul Sohar,E. Tracy Turner Jones,Robert A. Reamer,F. E. Roberts,Edward J. J. Grabowski +9 more
Patent
Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor
Lili Feng,Sven Erik Godtfredsen,Piotr H. Karpinski,Paul Allen Sutton,Mahavir Prashad,Michael J. Girgis,Bin Hu,Yugang Liu,Thomas J. Blacklock +8 more
TL;DR: In this paper, a specific combination, linked prodrug or a compound of an angiotensin receptor antagonist and a NEPi, is used in the treatment of hypertension.
Journal ArticleDOI
A Practical and Chemoselective Reduction of Nitroarenes to Anilines Using Activated Iron
TL;DR: In this paper, the reduction of nitroarenes to anilines using activated iron generated by Fe/HCl or Zn/FeSO 4 was described, and a variety of functional groups such as alkyne, ketone, enone, nitrile, lactone, and aromatic halide were well tolerated under these conditions.
Journal ArticleDOI
LCZ696: a dual-acting sodium supramolecular complex
Lili Feng,Piotr H. Karpinski,Paul Allen Sutton,Yugang Liu,David Hook,Bin Hu,Thomas J. Blacklock,Philip E. Fanwick,Mahavir Prashad,Sven Erik Godtfredsen,Christoph Ziltener +10 more
TL;DR: LCZ696 is the first example of a dual-acting pharmaceutical built as a supramolecular complex delivering two pharmacologic effects—angiotensin receptor 1 (AT1) blockage and neprilysin (NEP) inhibition.